Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective ...

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...

Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

Joshua K. Sabari, MD, discusses the antitumor activity of second-line lurbinectedin, noting an ORR of 45%, a median DOR of ...

Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them ...

Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring ...

Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...